Supernus Pharmaceuticals
SUPN
225 hedge funds and large institutions have $1.33B invested in Supernus Pharmaceuticals in 2020 Q4 according to their latest regulatory filings, with 39 funds opening new positions, 73 increasing their positions, 83 reducing their positions, and 22 closing their positions.
254% more call options, than puts
Call options by funds: $4.77M | Put options by funds: $1.35M
200% more funds holding in top 10
Funds holding in top 10: 1 → 3 (+2)
77% more first-time investments, than exits
New positions opened: 39 | Existing positions closed: 22
24% more capital invested
Capital invested by funds: $1.07B → $1.33B (+$260M)
8% more funds holding
Funds holding: 209 → 225 (+16)
2.84% more ownership
Funds ownership: 97.62% → 100.46% (+2.8%)
12% less repeat investments, than reductions
Existing positions increased: 73 | Existing positions reduced: 83
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SIMG
Stephens Investment Management Group
Houston,
Texas
|
+$11.8M |
| 2 |
Fidelity Investments
Boston,
Massachusetts
|
+$9.16M |
| 3 |
ACM
Ashford Capital Management
Wilmington,
Delaware
|
+$8.7M |
| 4 |
Fuller & Thaler Asset Management
San Mateo,
California
|
+$6.86M |
| 5 |
GKIM
GW&K Investment Management
Boston,
Massachusetts
|
+$5.76M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SI
Sofinnova Investments
Menlo Park,
California
|
-$6.88M |
| 2 |
Acadian Asset Management
Boston,
Massachusetts
|
-$5.14M |
| 3 |
Morgan Stanley
New York
|
-$3.78M |
| 4 |
Arrowstreet Capital
Boston,
Massachusetts
|
-$3.74M |
| 5 |
BlackRock
New York
|
-$3.58M |
SUPN Hedge Fund Activity: Q4 2020 in Review
225 of the 5,651 institutional investors tracked by Wall St. Rank reported a position in Supernus Pharmaceuticals (SUPN) for Q4 2020, worth a combined $1.33B — up 24% from $1.07B a quarter earlier.
Buyers outnumbered sellers: 39 funds opened new SUPN positions and 22 closed out — a net gain of 17 holders — while 73 added to existing stakes and 83 trimmed.
The largest buyer was Stephens Investment Management Group, adding an estimated $11.8M. The largest seller was Sofinnova Investments, exiting entirely with an estimated $6.88M sold.
- 225 institutional investors held Supernus Pharmaceuticals (SUPN) as of Q4 2020, up from 209 in Q3 2020.
- Funds reported $1.33B of Supernus Pharmaceuticals stock for Q4 2020, up 24% quarter-over-quarter.
- 39 funds opened new Supernus Pharmaceuticals positions in Q4 2020 and 22 closed out, a net change of +17 holders.
- The largest Supernus Pharmaceuticals buyer in Q4 2020 was Stephens Investment Management Group, an estimated $11.8M added.
- The largest Supernus Pharmaceuticals seller in Q4 2020 was Sofinnova Investments, an estimated $6.88M sold.
Based on aggregated 13F filings for Q4 2020.